HPR26 Managed Entry Agreements to Mitigate Uncertainties and Reimbursement Challenges for Orphan Drugs: A Matrix to Determine Their Suitability
Abstract
Authors
M Callenbach S. van den Berg A Hulsbosch C Hollak C Leopold A.K. Mantel-Teeuwisse W Goettsch